Tricuspid Regurgitation (TR)
Conditions
Brief summary
The purpose of the study is to evaluate safety and effectiveness of the TRiCares Topaz TTVR system for treatment of subjects presenting with clinically relevant tricuspid regurgitation who are suitable for valve replacement.
Detailed description
The TRICURE US IDE Pivotal Study is a prospective, global, multi-center, randomized (1:1) controlled study (RCT) designed to evaluate the safety and effectiveness of the TRiCares Topaz TTVR System compared to the Edwards EVOQUE TTVR System in subjects with severe or greater tricuspid regurgitation.
Interventions
TRiCares Topaz TTVR System
Edwards EVOQUE TTVR System
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient is ≥ 18 years of age * Patient has severe or greater tricuspid regurgitation with symptoms despite optimal medical therapy * Patient is an appropriate candidate to undergo TTVR as determined by the Institution Heart Team
Exclusion criteria
* Patient has a tricuspid device currently in place * Patient has anatomical contraindications * Patient is in need of urgent surgery * Patient has a left ventricular ejection fraction of \< 25% * Patient has life expectancy of \< 1 year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Major Adverse Events (MAE) | 30 days post-procedure | — |
| Composite Endpoint | 1 year post-procedure | All-cause mortality, heart failure hospitalization, non-elective tricuspid valve reintervention |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in qualify of life (QoL) | 1 year post-procedure | as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline |
Contacts
Piedmont Hospital
Unity Health Toronto